Blueprint Medicines

Blueprint Medicines is a Cambridge, Massachusetts kinase medicine company, now a Sanofi company. Its approved product, Ayvakit/Ayvakyt (avapritinib), is a KIT and PDGFRA inhibitor approved for advanced and indolent systemic mastocytosis and, per the company's site, for certain gastrointestinal stromal tumours (GIST). The pipeline includes elenestinib, a next-generation KIT inhibitor for systemic mastocytosis, and BLU-808, an oral wild-type KIT inhibitor for mast cell-driven allergic and inflammatory disease. Sanofi and Blueprint announced a definitive agreement on 2 June 2025 at 129 US dollars per share in cash (about 9.1 billion US dollars equity value) plus a contingent value right of up to 6 US dollars per share; the tender offer expired on 17 July 2025 with about 70.9 percent of shares tendered, and the merger was completed the same day, ending the Nasdaq listing. Blueprint's former Nasdaq ticker was BPMC.